Literature DB >> 25789838

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

Daniela Weiler1, Joachim Diebold, Klaus Strobel, Stefan Aebi, Oliver Gautschi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25789838     DOI： 10.1097/JTO.0000000000000424

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

Review 1.  Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Authors:  Janakiraman Subramanian; Archana Katta; Ashiq Masood; Dashavantha Reddy Vudem; Rama Krishna Kancha
Journal:  Oncologist       Date:  2019-07-10

2.  Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Authors:  Bob T Li; Ronglai Shen; Darren Buonocore; Zachary T Olah; Ai Ni; Michelle S Ginsberg; Gary A Ulaner; Michael Offin; Daniel Feldman; Todd Hembrough; Fabiola Cecchi; Sarit Schwartz; Nick Pavlakis; Stephen Clarke; Helen H Won; Edyta B Brzostowski; Gregory J Riely; David B Solit; David M Hyman; Alexander Drilon; Charles M Rudin; Michael F Berger; Jose Baselga; Maurizio Scaltriti; Maria E Arcila; Mark G Kris
Journal:  J Clin Oncol       Date:  2018-07-10       Impact factor: 44.544

3.  ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.

Authors:  Jody C Chuang; Henning Stehr; Ying Liang; Millie Das; Jane Huang; Maximilian Diehn; Heather A Wakelee; Joel W Neal
Journal:  J Thorac Oncol       Date:  2017-02-04       Impact factor: 15.609

Review 4.  Chemotherapy remains an essential element of personalized care for persons with lung cancers.

Authors:  M D Hellmann; B T Li; J E Chaft; M G Kris
Journal:  Ann Oncol       Date:  2016-07-25       Impact factor: 32.976

5.  Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.

Authors:  Karen L Reckamp; Tejas Patil; Kedar Kirtane; Thereasa A Rich; Carin R Espenschied; Caroline M Weipert; Victoria M Raymond; Rafael Santana-Davila; Robert C Doebele; Christina S Baik
Journal:  Clin Lung Cancer       Date:  2020-06-20       Impact factor: 4.840

6.  Herceptin responsive lung adenocarcinoma in the setting of bilateral synchronous lung primaries and breast carcinoma.

Authors:  Gerard J Fitzmaurice; Michael Moore; Waris Ahmad; Ronan J Ryan
Journal:  Ann Thorac Med       Date:  2017 Jan-Mar       Impact factor: 2.219

Review 7.  Activating HER2 mutations as emerging targets in multiple solid cancers.

Authors:  Claire M Connell; Gary J Doherty
Journal:  ESMO Open       Date:  2017-11-24

8.  AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies.

Authors:  Ferdinando Maria Milazzo; Anna Maria Anastasi; Caterina Chiapparino; Antonio Rosi; Barbara Leoni; Loredana Vesci; Fiorella Petronzelli; Rita De Santis
Journal:  Oncotarget       Date:  2017-04-04

Review 9.  Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.

Authors:  Huanhuan Xu; Qi Liang; Xian Xu; Shanyue Tan; Sumeng Wang; Yiqian Liu; Lingxiang Liu
Journal:  World J Surg Oncol       Date:  2021-11-18       Impact factor: 2.754
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.